
Strong zzso are recommended for treating severe cancer pain in the advanced stages of the zzso Few data are available concerning the efficacy of zzso in cancer zzso We compared zzso zzso 70 zzso zzso zzso to zzso in an enriched design zzso zzso patients with cancer pain requiring strong zzso in the dose range of zzso zzso oral zzso zzso entered a two-week zzso phase, during which they were converted to zzso zzso Patients who could be stabilized on zzso zzso were zzso to zzso zzso or zzso patch for a two-week maintenance zzso zzso medication zzso zzso zzso zzso was allowed as zzso Response was defined as a mean pain intensity of zzso zzso zzso and a mean daily zzso zzso tablet intake of zzso or zzso zzso during the maintenance zzso Of zzso patients who entered the zzso phase, 100 discontinued treatment due to lack of efficacy or adverse zzso 189 patients continued treatment in the maintenance phase zzso zzso zzso 95 zzso of whom 31 discontinued treatment (7 zzso zzso 24 zzso A significant difference in the number of treatment zzso was zzso 70 zzso zzso zzso zzso zzso 47 zzso zzso zzso zzso This result was supported by a lower daily pain intensity, lower intake of zzso zzso zzso and fewer dropouts in the zzso zzso zzso The zzso of adverse events was slightly higher for zzso zzso In conclusion, zzso zzso 70 zzso is an zzso and safe treatment for patients with severe cancer zzso 

